Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Casodex, Zoladex , Lupron Clear all

Conditions: Prostate Cancer
Interventions: Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog; Radiation · Drug
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 106
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy; Device · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Androgen Deprivation Therapy, bicalutamide, bevacizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 4 more

Conditions: Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: Bicalutamide, Flutamide, Goserelin Acetate, Ipilimumab, Leuprolide Acetate, Pharmacological Study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Leuprolide, Goserelin, Sunitinib Malate, Casodex, Radiation Therapy (RT); Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Spartanburg, South Carolina • Houston, Texas

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 3
States / cities: Chicago, Illinois • LaGrange, Illinois

Conditions: Prostate Cancer
Interventions: Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire; Procedure · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 85 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Radiation · Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: Male only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Adenocarcinoma of the Prostate
Interventions: Stereotactic Radiosurgical Boost, Casodex, Leuprolide; Radiation · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer
Interventions: Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Docetaxel, Bevacizumab, ADT, Bicalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Brachytherapy; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron); Drug · Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Leuprolide Acetate; Drug · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 2
States / cities: Duarte, California • South Pasadena, California

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions: Abiraterone Acetate, Bicalutamide, Degarelix, Flutamide, Goserelin Acetate, Leuprolide Acetate, Nilutamide, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Micro RNAs to Predict Response to Androgen Deprivation Therapy

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer